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3. Magnitude of the problem:  
3.1. Atrial Fibrillation Epidemiology  
 Atrial fibrillation (AF) is the most common sustained heart rhythm disorder [1]. 
It has become an epidemic condition that constitutes a serious public health problem with 
a heavy impact on sanitary costs. Its prevalence will increase in the coming decades due 
to an ageing population (in Europe, in the year 2060, it is estimated that the number of 
people suffering from AF will increase to 17.9 million) [1]. Both the population and 
proportion of older people are increasing: from 2012 to 2032, the populations of those 
65–84 years old and over-85s are expected to increase by 39% and 106%, respectively. 
The risk of AF increases with age: about 1 in 200 people aged 50-59 have AF; this 
increases  to almost 1 in 10 people over 80. However,  evidence indicates that a large 
number of patients suffering from AF are being underdiagnosed and, thus, undertreated 
[2]. 
 Accurate information on AF’s prevalence in the general population is, therefore, 
not widely available. Some European countries have undertaken screening studies to 
estimate the proportion of the population affected. These studies reported rates in the 
general population ranging from 1.3% (UK, Italy) to 3.9% (Greece), with rates being 
highly dependent on age. Less data is available from Central and Eastern European 
countries. A pilot multicentric study (AFABE Study [3]) in the County of Terres de l'Ebre 
involved 1043 randomly selected patients older than 60 years of age. All of the patients 
underwent an ECG and different medical variables, such as CHA2DS2VASC and HAS-
BLED scores, international normalized ratio results and reasons for not receiving 
anticoagulant therapy, were observed and recorded. The study's various outcomes were: 
1) the prevalence of AF increased with the patients’ ages (1.2% in patients between 61 to 
64 years old to 20.7% in those 85 years and older); 2) the prevalence of AF was higher in 
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male individuals (except in the group of 85 years and older); 3) the prevalence of 
hypertensive and diabetic patients was greater than that associated with other risk factors; 
the prevalence of AF indicated in the clinical history of the patients was 8.7%; 96.7% of 
the patients with a previous diagnose of AF had 2 CHA2DS2VASC scores; 4) it was 
observed that the prevalence of previously undiagnosed AF was 2.2% (CI95% 1.3-3.1%); 
(5) and, among others, the percentage of patients diagnosed with AF that were not treated 
with anticoagulant therapy was 24.35% (mainly due to CHA2DS2VASC scores <2 points, 
cognitive impairment and high risk of haemorrhaging). These results that were observed 
in our territory revealed the need to diagnose as many unknown AF cases as possible and 
treat those patients if indicated.  
  
3.2. Risk of stroke and associated comorbidities 
Evidence suggests that AF is one of the major causes of morbidity and 
cardiovascular mortality [4]. It increases death risk, congestive heart failure and the risk 
of systemic embolism, including stroke [5], and it is associated with a high risk of 
cognitive impairment, with or without a history of clinical stroke [6]. 
Studies in the general population [7] have also provided evidence that higher AF-
risk is related to higher CHA2DS2VASc scores, higher stroke incidence and higher 
Pfeiffer scores, but the exact mechanisms are unclear. Structural and functional 
alterations of cerebral blood vessels have emerged as key correlates of conditions 
associated with cognitive impairment. In this way, targeting the stroke risk factors would 
not only reduce stroke, but also reduce cognitive impairment. Stroke and dementia are 
risk factors for each other and share some of the same, largely modifiable, risk and 
protective factors in asymptomatic individuals. Effective strategies for improvement in 
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the initial phases of the disease would have a massive beneficial impact on health care 
systems.  
AF is often not diagnosed until after a stroke event and is not treated according to 
widely available, national, evidence-based guidelines. AF is estimated to increase the risk 
of stroke 3- to 5-fold and to be associated with around a quarter of all ischaemic strokes. 
Additionally, AF is associated with more severe strokes, leading to higher mortality and 
disability. AF is significantly more common in people who have had a stroke than in the 
general population. Reported prevalence rates are as high as 31-38%. Variation is also 
high both within countries and between studies with similar methodologies. Studies from 
Ireland[8], Iceland[9], Croatia[10] and Norway[11] reported that between a quarter to 
over half of AF diagnoses after stroke were unknown before. A recent meta-analysis also 
reported that 24% of stroke patients are newly diagnosed with AF after their strokes [11]. 
These reports again suggest a significant under-diagnosis of AF in the general population. 
Better detection rates of AF could lead to improved primary prevention. Over the last 25 
years, the number of AF-related ischaemic strokes has trebled in adults over 80 years and 
is predicted to treble again by 2050. 
Although the risk of AF-related stroke can be reduced by 64-70 % using oral 
anticoagulants [12], underutilization of this effective treatment and delayed diagnosis 
remain major obstacles. Around a quarter of patients have silent or asymptomatic AF [13] 
and up to 25% of patients with AF-related stroke only have this arrhythmia diagnosed at 
the time of the stroke. People with AF who suffer a stroke have greater mortality, more 
disability, more severe strokes, longer hospital stays and lower rates of discharge to their 
own homes compared to those without AF [14]. AF-related strokes are more likely to 
recur and fear of another stroke is likely to cause anxiety and affect quality of life (which 
cost 45 billion euros in 2015) [15]. Patients being newly admitted with stroke may 
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eventually lead to greater anguish for their families and larger health costs from extensive 
hospital assessment, including brain scans, admission to specialist stroke units and 
multidisciplinary specialist assessments from a range of healthcare professionals 
including physicians, physiotherapists, occupational therapists, clinical psychologists and 
speech and language therapists. Over time, patients are likely to require treatment for 
complications and rehabilitation therapy and have ongoing health and social care needs. 
Around 40% of discharged patients need help with daily activities. Nearly one-fifth had 
help solely from unpaid careers and approximately two-thirds from only paid careers, 
with the remainder receiving help from both. Eighteen percent needed three or more visits 
a day from social services. Eighty-five percent of patients required physiotherapy. Forty-
eight percent required speech and language therapy. AF-related strokes are a great burden 
for patients. An important factor in the economic burden of AF relates to the detection of 
the condition. As noted earlier, AF is currently often only detected after a stroke; earlier 
AF detection and intervention to reduce stroke risk could reduce the occurrence of AF-
related strokes and the associated economic burden. 
The evidence suggests that AF is associated with a high risk of cognitive 
impairment as an independent risk factor with or without a history of clinical stroke. 
Fifteen to 20% of individuals aged over 65 years will suffer some degree of cognitive 
deterioration [6]. However, silent infarctions of the brain are even more frequent than 
symptomatic strokes [16]. Silent strokes remain undetected in most cases but can 
accumulate over time to cause or aggravate pre-existing cognitive impairment. In 2015, 
the estimated number of individuals with dementia in the world was 47.47 million, and 
this is expected to increase to 75.63 million by 2030 and 135.46 million by 2050 [17]. 
Therefore, the incidence of dementia will double every 5.9-years age increase, i.e., from 
3.1/1000 person-years at age 60-64 to 175/1000 person-years at age ≥95.  
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Patients with AF and cognitive impairment [17] are more likely to be women, 
older and have a higher baseline burden of functional dependence in daily activities, 
higher cognitive impairment prevalence and higher mortality. In spite of preliminary 
reports indicating that anticoagulation can reduce the risk of cognitive impairment in 
patients with AF [18], AF is underdiagnosed [19]. Patients are undertreated with 
anticoagulation, with cognitive impairment being the main reason for not receiving oral 
anticoagulant therapy. Cognitive impairment was found to double mortality.   
In our territory [20], patients with AF were on average older than patients without 
AF, a larger proportion was male and aged ≥80 years, they had a higher prevalence of 
heart failure (HF), higher Barthel scores and Charlson scores and a higher incidence of 
mortality than those without AF. Data from our primary care records [21] allowed us to 
uncover a major care gap in stroke prevention: the prevalence of undetected AF and its 
association with an increased risk of cognitive impairment, heart failure, sudden death 
and cardiovascular morbidity [22]. Despite progress in AF diagnosis and management 
[17], the prevention of stroke remains the cornerstone. In the group with known AF, 
23.5% were not receiving oral anticoagulant therapy (OAT). The odds ratio for not being 
treated with OAT was 2.04 (95%CI 1.11-3.77) for women and 1.10 (95%CI 1.05-1.15) 
for more advanced age at diagnosis. Cognitive impairment (15.2%) was the main reason 
for not receiving OAT. Despite these challenges, interviewees from across countries and 
stakeholder types reported that policymaker awareness of AF is low and that AF is viewed 
as a medical issue rather than a public health issue. 
 
3.3. Global burden of atrial fibrillation and economic cost 
 Due to demographic ageing, in Europe, the prevalence of AF is estimated to 
increase from 1.9% (2008) to 3.5% (2050) and the number of AF-related ischaemic 
strokes in people >80 years will triple (2010-2060). If we consider that more than 60% of 
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strokes occur in people older than 80 years of age, the proposed objective is extremely 
important. Approximately one-third of ischaemic strokes are related to the presence of 
unknown AF. In this case, strokes are more severe, more disabling, associated with 
cognitive decline and pose a higher risk of institutionalization than strokes from other 
causes [23]. 
Most patients with AF require long-term pharmacological treatment, often 
including warfarin or acenocoumarol. Monitoring anticoagulant treatment is expensive. 
AF also leads to hospitalization and is a cause of particularly costly cardiovascular 
morbidity—that is, stroke and heart failure. The number (and rate) of AF-related 
hospitalizations (both primary and secondary) has increased two-fold to three-fold in 
recent years. Consequently, AF is likely to impose a substantial and growing economic 
burden on health care systems. 
 In addition to the epidemiological predictions associated with demographic 
ageing, the greater cardiovascular comorbidity, frequency, average drug consumption, 
mortality and severity of the associated stroke would confirm the predicted increase in 
costs associated with the treatment of AF, especially in association with a stroke episode. 
Obviously, the impact will depend on both size and demographic composition. The 
presence of a progressive increase in the prevalence and severity of cognitive decline with 
the risk of AF increases the magnitude of the impact and reinforces the possible 
etiopathogenic interrelation between both processes in the general population, as well as 
the need to protocolize its detection. A model of comprehensive care for AF showed a 
45% reduction in mortality from any cause [23], but its analysis is subsequent to the 
diagnosis of AF. 
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3.4. The need for screening/case finding 
AF satisfies most of the World Health Organization’s criteria for a disease suitable 
for screening (Figure 1 Appendix). Good AF management is essential to prevent stroke, 
but little has changed: guidelines are not fully implemented, many AF cases are not 
diagnosed before a stroke episode, patients are not given anticoagulants, many of those 
taking anticoagulants do not have quality criteria for good anticoagulation (TRT >60%) 
and there is postcode variation in the management and use of Direct Oral Anticoagulants 
(DOACs). Although many patients with AF develop symptoms that lead to appropriate 
diagnosis and management, the first manifestation may be a debilitating stroke or death. 
Finding AF before symptoms manifest could lead to the initiation of appropriate effective 
therapy to reduce stroke and death and potentially the initiation of risk-factor 
modifications to reduce complications from AF progression. A significant proportion of 
people with AF are diagnosed by chance during health assessments carried out for other 
reasons, or due to having a stroke. There may be multiple reasons for under-diagnosis, 
including the fact that AF can be asymptomatic and a lack of awareness about the 
condition and its symptoms. 
 The detection of AF can have important implications for reducing the risk of 
stroke and its large clinical and economic effects. Thus, different screening and case-
finding strategies have been proposed and recommended by international organizations 
such as the European Society of Cardiology (ESC), Stroke Alliance for Europe (SAFE), 
National Institute for Health and Care Excellence (NICE), European Heart Rhythm 
Association (EHRA), World Health Care Forum (WHF), European Primary Care 
Cardiovascular Society (EPCCS) and others. Different organisations have different 
positions about whom to screen or to whom to aim case-finding [24-26]. For a screening 
program to be efficient, the screening technique must have a high positive predictive 
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value using a low-risk tool at low cost. Screening yield depends on disease prevalence 
and diagnostic test performance. 
 Opportunistic screening/case finding, where patients are checked for AF when 
they visit doctors for other reasons, is widely supported as a means to achieve higher rates 
of detection to enable early intervention. Primary care is an ideal setting: in addition to 
regular primary care physician visits, nursing support for screening is available and there 
is a direct link with the practitioner to prescribe OAC. Two challenges remain unsolved: 
1) developing a sustainable strategy for detecting undiagnosed AF and 2) providing 
adequate treatment for patients with known or newly discovered AF because 
undertreatment is common. In primary care, regarding the methods of mass screening, 
handheld ECG devices have the advantage of providing a verifiable ECG trace that 
guidelines require for AF diagnosis and would, therefore, be preferred as screening tools. 
The AF diagnosis requires at least 30 s of absolutely irregular RR intervals and no 
discernible, distinct P waves on the electrocardiogram (ECG) [27]. Settings for screening 
include various venues in both the community and the clinic, but they must be linked to 
a pathway for appropriate diagnosis and management for screening to be effective 
(Figure 2 Appendix). Opportunistic screening was tested against routine screening in the 
SAFE study, which found that opportunistic screening improved routine practice, 
whereas routine screening did not [1]. It can also be used in the community, in both high- 
and low-middle-income countries.  In the clinic, it is usually performed by physicians or 
nurses, whereas in the community, non-physician health professionals and laypeople can 
be trained to detect pulse irregularity. Pulse checks, either done at home by the patients 
themselves or in GP surgeries or pharmacies, are a simple and effective way of checking 
for AF and should be used more.  
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 Innovation in technology has produced new screening devices (Figure 3 
Appendix) that improve the feasibility and cost-effectiveness of widespread screening 
and are easily available in primary care. These devices are recognized as valid for AF 
detection by the European Primary Care Cardiovascular Society and could be used to 
complement traditional screening by pulse palpation [28]. There are ongoing studies to 
determine the sensitivity and specificity of these new tools. Adding biomarkers (e.g. 
natriuretic peptides, high-sensitivity troponin) [29] to existing clinical predictors may 
improve the prediction of AF incidence. However, there are marginal improvements in 
model discrimination and reclassification. Continuous monitoring coupled with a 
diagnostic algorithm could detect paroxysmal AF more effectively than repeated patient-
activated devices. Prolonged continuous ECG monitoring with external or subcutaneous 
recorders could diagnose more paroxysmal AF, but it requires further evaluation, so its 
cost-effectiveness is limited regarding the detection of AF with lower absolute stroke risk. 
Health resources are known to vary widely between countries and health systems, so the 
setting for AF screening should be both country- and health-system-specific. 
Improvement in the diagnosis and management of AF is needed, including systematic 
approaches to identifying and monitoring AF (Figure 4 Appendix). The effectiveness 
and cost-effectiveness of AF-screening policies of at-risk populations should be assessed 
in the respective health contexts of each country, as should new developments such as 
devices and apps for detecting AF, the self-monitoring of INR and new anti-coagulation 
therapies. A more systematic approach to monitoring guideline adherence (e.g. national 
or large regional audits), and possibly incentivising this adherence, might improve 
treatment rates [30]. 
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3.5. Summary of Studies Regarding Screening for Atrial Fibrillation (Table 1 
Appendix) 
 In the year 2017, the AF-SCREEN International Collaboration White Paper was 
published in Circulation [31]. It showed whom to screen, where to screen and how to 
screen for AF (Figure 4 Appendix). The preferred recommendations are to screen people 
aged >65 years or those patients with AF that are undertreated, to do so at Primary Care 
or Specialist clinics and for screening to be done first using opportunistic pulse palpation 
and then an ECG, or a single-lead ECG or to do so post-stroke. 
 Several prospective controlled and non-controlled studies have examined the 
effect of screening on the detection rate of previously undiagnosed AF, using a range of 
different screening programmes and target populations. These studies are summarized in 
Table 1 of the Appendix (Table 12.2.1).  Several in-progress trials may strengthen the 
evidence base for screening. The most common target population for screening was those 
aged ≥65 years in a primary care setting, with screening being carried out 
opportunistically at GP appointments or pharmacy visits or through invitation to an ECG. 
Many worldwide projects from various health collectives have been formed to try to 
screen as many populations as possible. One of the latest types of study to try to detect 
AF (due to the easy access of the population) are those initiated by pharmacies such as 
the PIAAF study in Canada [32], among others [33-35]. They agree on the same 
conclusion: opportunistic screening for AF in pharmacies is feasible and allows 
identifying people with previously unknown AF. 
 In order to improve the detection of silent AF, opportunistic screening for AF in 
all patients ≥65 years using the pulse has been recommended by ESC guidelines since 
2012 [7] and is recommended by EHRA guidelines. Opportunistic screening by pulse-
taking or ECG strip received a class I level of evidence B recommendation in the most 
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recent ECG guidelines. Yet, it may be questioned whether the yield of this opportunistic 
way of screening is sufficient in higher-risk patients and whether it should be extended to 
younger individuals. Further, systematic screening in higher risk groups may even be 
warranted. The first large-scale screening trial was the Screening for AF in the Elderly 
(SAFE) trial. The principal conclusion from the SAFE study was that active screening 
can identify an additional one-third of AF cases. Additional main studies on AF screening 
include the LOOP-Study, all of the PIAAF studies, the STROKESTOP Study and others 
(Table 1 Appendix). Opportunistic screening identified as many of these cases as 
systematic screening for considerably less effort, so it should be promoted in primary care 
as long as a high level of coverage can be maintained [8-9] (Figure 5 Appendix).  
 According to the evidence described above, it can be assumed that opportunistic 
screening is now recommended in patients ≥65 years. It may even be started at a lower 
age in the presence of a higher CHA2DS2-VASc score (CHA2DS2-VASc ≥2 in 
individuals ≥55 years). The need for systematic screening is still uncertain. So far, no 
clear advantage of systematic above opportunistic screening has been demonstrated.  
AF is often asymptomatic and screening is not routinely undertaken in Europe. In 
most European countries, ESC guidelines have been assumed and are commonly used 
[36-38]. Although individuals with AF often have other diseases and disorders—
including ischaemic heart disease, heart failure, hypertension, diabetes and 
hyperthyroidism—age has been identified as the strongest independent risk factor for AF. 
Screening studies also found that between 10% and 66% of people with AF were 
previously unknown cases (Belgium, Portugal, UK, Spain). This implies a significant 
under-diagnosis in Europe. A major screening study has been launched in Sweden to 
detect AF and to see whether screening reduces stroke incidence and is cost-effective 
[39]. 
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The Belgian Heart Rhythm Association, with the contribution of two 
pharmaceutical industry sponsors, organizes the yearly Week of the Heart Rhythm [40], 
which involves free mass screening events and the distribution of information leaflets 
about self-administered pulse checks. A study on mass screenings, involving 69 hospitals 
that screened a total of 13,564 patients, found that these screenings are feasible and 
effective in detecting AF in approximately 2.2 per cent of the screened individuals. The 
French AVC Association launched a campaign to raise awareness about AF in reaction 
to a recent survey in France that showed that 87 per cent of people surveyed do not know 
what AF is. In 2013, the campaign covered 4,592 patients in 16 French cities by educating 
general practitioners on AF and modes of detection [41]. Five hundred and eighty-five 
patients (15.6%) were referred to cardiologists and 129 new AF cases were 
confirmed. The achievements of this campaign included increased awareness of 
cardiovascular disease (including AF and AF-related stroke), the integration of AF and 
AF-related stroke into a cardiovascular policy document and a call for increased political 
engagement on cardiovascular disease (including AF and AF-related stroke) as part of a 
broader commitment to public health. The German Stroke Foundation (Stiftung Deutsche 
Schlaganfall-Hilfe) sees regular pulse self-measurement as the best way to find 
irregularities in the heart rate and identify AF early [42]. The AF guidelines of the Italian 
Association for the Fight Against AF (ALFA 2014) note that patients who do not present 
symptoms are often not aware of their condition. The guidelines claim that if all 
individuals with AF were identified, the number of patients would double. The 
Association’s patient information publication recommends that patients self-monitor their 
pulse at least once a week [43]. The Association created a campaign in 2014 to raise 
awareness of the importance of self-performed pulse checks.  
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A 2011 survey of NHS Primary Care Trusts (PCTs) found that while not 
compulsory, many encourage GPs to include pulse checks in their NHS Health Checks. 
NHS Health Checks are aimed at adults in England aged between 40 and 74 to help lower 
the risk of developing four common diseases: heart disease, stroke, diabetes and kidney 
disease. However, the 2011 survey also found that 26 per cent of NHS Health Checks did 
not include pulse checks. The ‘Know Your Pulse’ campaign, jointly launched by the AFA 
and Arrhythmia Alliance in 2019 [44], organises yearly awareness-raising campaigns on 
the risks of AF and stroke and offers guidance on pulse self-checks. 
A survey completed by respondents from 33 European Heart Rhythm Association 
Research Network partners in 16 countries found that there is currently no consensus 
regarding the screening methods for asymptomatic AF. Opportunistic screening, in the 
form of a peripheral pulse check, should be carried out regularly for adults 65 years and 
older. Opportunistic screening in this group is recommended by the European Society of 
Cardiology and in the United Kingdom by the Royal College of Physicians of Edinburgh 
[45]. Indeed, opportunistic screening (compared to targeted screening) was the only 
strategy that improved on routine practice. A systematic review found that single time-
point screening in adults 65 years or older identified previously unknown AF in 1.4 per 
cent of the screened population. 
Case finding or primary screening, depending on the circumstances, is firmly 
recommended for diagnosing and treating as many patients as possible in different ambits 
and situations. It has been recommended as an easy manoeuvre to prevent stroke [46] and 
post-stroke [31] in the general population [47], in a population selected with a risk model 
[48], in metropolitan and rural areas by general practice [49] and in many other different 
populations and places. In our territory, Terres de l'Ebre (Tarragona, Spain), before 2012 
there was no defined pathway for AF.  
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 First, we evaluated the work done by the AFABE Study in the same territory, 
which had 48,336 patients. The new results show that a proper case finding for AF is 
feasible and is associated with an increase in the prevalence of AF. The same study also 
identified some of the real barriers that patients face in our health system regarding case 
finding for AF, which in our territory is guided mainly by GPs. 
 There remains little doubt that proper screening or case finding for AF is 
necessary. Many nuances are still not properly described: for example, different age 
ranges, which specialist should screen and many other variables. Nowadays, there is an 
important movement to screen high-risk patients for AF [48,11], as well as those with a 
heavy AF burden [50].   
  The AFRICAT Study (NCT 03188484) is another study on AF that was carried 
out in our territory. Its main hypothesis involved evaluating patients who had a high risk 
of developing AF to discover certain clinical characteristics that could be used to optimize 
screening strategies; as a second hypothesis, the study proposed that a combined approach 
integrating biological (blood biomarkers) and electrocardiographic information could 
achieve better accuracy than either of them separately. The global objective of the 
AFRICAT project was the development and validation of a multimodal sequential 
screening program for AF at primary care in high-risk individuals (patients with ages 
between 65 to 75 years with previous diagnoses of hypertension and diabetes). The main 
results were: first, the AFRICAT study shows ways to improve the diagnosis of AF in 
primary care; second, a 5-year predictive clinical model of AF in its population was 
validated in an independent sample; third, it found comparative results between different 
AF detection devices characterized by their high specificity; fourth, biomarkers could 
prove to be really useful in predicting AF risk, although the authors do not have cut-off 
points at different risk levels; finally, and probably most importantly, Holter monitoring 
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(for 30 days) in patients at high risk of AF could double the prevalence of previously 
known AF. 
 Various scales for measuring the risk of developing AF are being defined, which 
could ease the work of stratifying populations to screen. The most accepted and studied 
scale is the CHARGE-AF [51], which has been compared to the CHA2DS2VASC score 
[52]. The CHARGE-AF scale has been proven to be the most suitable for primary 
screening. 
 With all this data, in our second study, taking into account the worldwide expert 
recommendations, the conclusions from the AFRICAT Study and different high-risk 
scales, we focused on more finely identifying those patients that could suffer from AF 
from the primary care point of view. In this second study, various biomarkers were 
analysed and compared to one-month Holter monitoring to find an accessible tool for GPs 
to use as a screening biomarker in a defined high-risk population.  
There are some current studies evaluating various wrist devices for daily use. 
These studies are still very early and are being evaluated on a large scale, but the results 
are promising and could contribute to massive population screening in a few years, which, 
associated with predictive models of population risk, echocardiography criteria and 
specific biomarkers, may further help us to find unknown AF [53,54]. However, there is 
currently no evidence for their use in screening. 
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4. Hypothesis 
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4. Hypothesis  
 
H0.1 (First article): Case finding strategy increases the detection of AF compared to the 
usual routine clinical practice.  
 
H0.2 (Second article): The use of N-Terminal Pro B-Type Natriuretic Peptide makes a 
difference in the detection of unknown AF in asymptomatic high-risk populations in the 
context of a screening programme. 
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5. Objectives 
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5. Objectives 
5.1. Primary objective/s 
 To evaluate the effectiveness of AF case finding in the general population ≥ 
60 years and older relative to usual clinical practice. 
 To identify possible barriers to and enablers of opportunistic community AF 
case finding. 
 To determine the usefulness of N-Terminal Pro B-Type Natriuretic Peptide's 
usefulness as a biomarker in asymptomatic high-risk populations for atrial 
fibrillation in the context of a screening programme. 
5.2. Secondary objectives 
 To propose an atrial fibrillation pathway, mainly from primary care, to 
establish early diagnosis. 
 To target the most at-risk population to increase the screening’s effectiveness.  
 
This study, therefore, investigates possible social and clinical barriers to 
opportunistic community screening for AF and tries to target screening with a biomarker 
feasible for use in primary care to diagnose more AF. 
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6. Materials and methods 
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6. Material and methods 
This study has two different phases focusing on different populations with 
different materials and methods, but these phases share the same purpose of finding a 
common AF pathway.  
In 2015, the population from the County of Terres de l’Ebre, Tarragona, Spain, 
participated in a pilot study in collaboration with the Master Plan for Cerebral Vascular 
Malaltia / Agència de Qualitat i Avaluació Sanitàries de Catalunya (PDMVC) and the 
Estratègia d'Atention Integral a la Cronicitat for the design of an AF route with the general 
objectives of improving the care of people with AF, coordinating different levels of care, 
promoting excellent clinical practice and reducing AF-related morbidity and mortality, as 
well as health outcomes. For this reason, the initial objective was: “palpation of the 
arterial pulse and/or ECG and its registration in the electronic medical record (e-cap) to 
any citizen ≥60 years of age who contacted the health system, especially in care primary". 
For said registration, a specific variable (rhythmic/arrhythmic) was introduced in the e-
cap, section on Prevention and Promotion of Health Activities, which appears in a 
different colour when the citizen belongs to the target group and has not carried out the 
activity. 
The first part of this study was an observational, cross-sectional, multi-centric and 
non-interventional study in the context of ordinary primary care practice involving the 
population of the County of Terres de l’Ebre, Tarragona, Spain, ≥ 60 years of age (n = 
51410) with an active clinical history (e-cap), of which 48,336 patients without known 
AF were included. The main variable was whether a patient’s heartbeat is rhythmic or 
arrhythmic, as described in the record of the patient’s medical history of case finding 
activity for AF during the period from 1 January 2016 to 31 December 2017, confirmed 
with a 12-lead ECG. Secondary variables were also studied and analysed, such as 
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sociodemographic variables, case identification code (the numbering of the Individual 
Health Card was used), age, sex and municipality of residence (>10,000 inhabitants, 
urban; 10,000-1000 inhabitants, semi-rural; <1,000 inhabitants, rural). Clinical relevant 
information and comorbidities were obtained from the coded diagnoses in the patients’ 
medical histories in both primary and hospital care (the codes of the International 
Classification of Diseases version 10 used to select the different AF entities were I48 as 
the main diagnosis). The CHA2DS2VASc scale was included. Cognitive impairment was 
evaluated by Pfeiffer scale (0-10): [0-2 errors] = normal; [≥ 3 errors] intermediate to 
severe involvement. The study recorded whether the patient was diagnosed as a Chronic 
Complex Patient [20]. Prescription information was recorded, including all drugs 
prescribed by any active diagnosis in an individual's medical history, with “poly 
medication” defined as the prescription of ≥5 different medications simultaneously. An 
evaluation of the use of direct anticoagulants and antivitamin K was carried out. Health 
service variables were considered, such as counting the number of visits to GPs and 
hospital doctors during each year and whether the patient had been institutionalized.  
AF was detected either through direct AF case finding activity or without a direct 
AF screening procedure. Both were done by pulse palpation and/or registration of an ECG 
in an asymptomatic patient who was subsequently recorded in the e-cap program. This 
activity was performed either by consultation with a physician or nurse at the primary 
care centre or by a home visit. If a pulse palpation suggested an arrhythmia, it was 
immediately followed by an ECG. Thus, a twelve-lead ECG record verified by a 
physician was used to define AF. 
A descriptive analysis of the sociodemographic and clinical variables was 
performed using the informatics programme SPSS 20.0, with the help of a statistician, to 
describe the frequency and percentage of the categorical variables and the mean and 
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standard deviation of the continuous variables. The adjusted prevalence and incidence of 
new AF were calculated, as was the number of screens required to diagnose new AF 
(NNS). This descriptive analysis was stratified according to whether the screening had 
been performed. To detect if there are statistically significant differences between these 
variables and the performance of the screening or not, the Chi-square independence test 
was performed on the variables; Crude and adjusted Odds ratios (multivariate model) 
were calculated to measure their associations with the performance of the screening using 
logistic regression. To calculate the goodness of fit of the multivariate model, a variable 
was created with the model's prediction probabilities and its ROC curve was calculated. 
A variable was created that included the factors associated with a significantly lower risk 
of performing opportunistic screening: <70 years of age, urban residence, 
institutionalization, Pfeiffer scale value ≥2 and number of visits to the primary care 
physician in 2017 ≤7. The adjusted odds ratio was calculated by logistic regression for all 
variables to measure the association of this variable with the screening. 
The study’s effectiveness was assessed based on changes observed in the 
prevalence of AF after two years of programme intervention and by comparing the 
incidence of newly diagnosed AF in the group with case finding as compared to the 
incidence in the control group (without AF case finding). 
Following these findings, for the second phase of the AF study of Terres de 
l'Ebre’s inhabitants, a population at risk for AF was defined. The intention of this part of 
the study was that, after demonstrating that performing atrial fibrillation screening and 
knowing what barriers we faced when carrying out case finding on patients, it was of 
great interest to apply a more complete study on subjects with high AF risk using clinical, 
biological and electrocardiographic registers to identify more AF cases. This second part 
of the study was an observational, multicentre, population-based study with the aim of 
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developing a screening programme to detect new cases of AF in high-risk individuals in 
primary care centres. It took place in the same County as in the first part of the study and 
involved randomly selecting 100 subjects aged 65–75 diagnosed with hypertension and 
diabetes from primary care between January 2016 and December 2017 out of a database 
consisting of 5,500 hypertensive and diabetic patients included in the AFRICAT project’s 
database (NCT03188484).  
The selected participants were ambulatory patients in a stable health situation (all 
individuals with chronic inflammatory diseases, cancer or dementia were excluded). The 
patients and their GPs arranged a visit to their primary care centre in which they received 
a comprehensive assessment consisting of clinical characteristics; an ECG was performed 
and a blood sample was extracted in EDTA and serum tubes to evaluate various blood 
markers (NT-proBNP, serum ApoC-III, plasma uPAR…) that could help predict AF. 
Patients were monitored with a Holter device for 4 weeks (trying to wear it for 23 hours 
every day and charging for 1 h) and the records were sent together with the ECG for 
blinded reading to the Rhythm Disorders Unit at the Cardiology Department of Hospital 
Virgen del Rocio in Seville to verify AF episodes. AF was defined following AHA 
guidelines as irregular R-R intervals without a P wave signal, lasting for more than 60 s. 
 Statistical analysis was also done using the informatics programme SPSS 20.0 
with the help of a statistician. The sociodemographic and clinical variables were 
analysed to describe the frequency and percentage of the categorical variables and the 
mean and standard deviation of the continuous variables.  
 In the bivariate analysis of normal distributions, the T-test was used for 
independent samples in the case of quantitative variables and the Chi2 test or Fisher's 
exact test in the case of categorical variables was performed to compare and study the 
population. ROC curves were obtained to calculate sensitivity, specificity and cut-off 
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values of NT-proBNP’s discrimination power. In the multivariable test, given the 
characteristics of this pilot sample and the number of significant variables in the 
regression, if the p-value is below a specified level of significance (α) (generally 0.10, 
0.05, or 0.01), the difference can be said to be statistically significant and reject the null 
hypothesis of the test. In this case, the value 0.09 was accepted as statistically significant 
due to the limitations of the pilot sample. 
Different variables were analysed to avoid duplication. Three probability variables 
were used to identify possible duplication (date of birth, sex and Individual Health Card 
identification number) so that each individual in the numerator was only counted once. 
Reviews were carried out every six months to detect possible deviations and errors, 
missing values and extreme values and to obtain control of the state of the investigation. 
The first part of this project was approved by the Ethics Committee for Scientific 
Research IDIAP Jordi Gol (code P18/118); for this type of study, formal consent is not 
required and the requirement for the informed consent of patients was waived prior to the 
inclusion of their medical data in this study. The protocol for the second part of the study 
was also approved by the clinical research ethics committee of IDIAP Jordi Gol (P15/047) 
and the Hospital Universitari Vall d’Hebron [PR (AG) 133-2015]; the formal consent of 
each patient was solicited and, if granted, the patients were included in the study. All data 
were included in an ad hoc repository, which was delivered to the main researcher in a 
completely anonymous format, supervised and assessed according to the General Data 
Protection Regulation of Spain/Europe of 1st February 2017. 
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7. Results 
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7. Results 
For the main result derived from the first part of the study, more cases of AF were 
directly detected from the case finding of the general population older than sixty years. 
The population included 48,336 patients with a mean age of 75 years and 87% of the 
population had CHA2DS2VASc scores ≥ 2; baseline characteristics are described in Table 
1 and in the first article (Appendix 12.3.1). Opportunistic AF case finding was performed 
in 61% of the population between 2016-2017. The average age was higher in the case 
finding group than in the control group, as was their associated comorbidity, 
CHA2DS2VASc scores, proportion of urban residence and frequency of primary and 
hospital care. The detection of new AF cases was significantly higher in the case finding 
group for all age ranges. From the case finding for AF, two hundred and one new cases 
were directly diagnosed. The prevalence of stroke and the number of patients receiving 
anticoagulant therapy were significantly higher in the presence of AF than in the group 
without diagnosed AF (p < 0.001).  
The prevalence of AF also increased through the end of the programme 
assessment (5.9% vs 7.7%, respectively; p <0.001). Two hundred and one previously 
undiagnosed cases of AF were accounted for by AF case finding: 26.3% of all new AF 
cases diagnosed. Stroke was also proven to be significantly higher in the presence of AF 
compared to the group without diagnosed AF (4.4% vs 1.6%; p <0.001).  
The sociodemographic variables associated with the lack of performance of case 
finding were age < 70 years, urban residence, institutionalised status, Pfeiffer score ≥ 2 or 
a record of ‘cognitive impairment’,  Charlson score ≤ 3 and a lower than average number 
of physician visits for the territory. 
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Table 1. Baseline characteristics of the population in the first part of the study 
 
At the same time as the first part of the study, having identified the barriers of the 
population in the case finding and to improve the efficiency of the applied screening 
method, we proposed using different biomarkers and electrocardiography in a high-risk 
population for AF to help identify more patients at risk of suffering from AF.  
 One hundred individuals were randomly selected from 5,500 hypertensive and 
diabetic patients aged 65-75 years. The clinical characteristics of the population used in 
this second part of the study can be found in Table 2 and in the second article (Appendix 
12.3.2). These demonstrated that coronary heart disease, heart failure, valvular diseases 
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and the use of anticoagulants were more common in AF individuals; CHA2DS2-VASc 
scores were also higher in patients suffering AF.  
Table 2. Baseline characteristics of the population in the second part of the study 
 
Out of the 100 individuals, 96 were monitored with an ECG Holter device, with a 
median monitoring time of 457 h. Few adverse events were described (mainly cutaneous 
rash). In 20 of these patients, AF was present (11 newly detected in the study). AF burden, 
defined as minutes being in AF divided by the total minutes of readable records, was 
calculated as a percentage. The median AF burden was of 10.35% (1.00-56.50).  
In the biomarker analysis, NT-proBNP, ApoC-III, sUPAR, vWF and ADAMTS13 
were analysed; inter- and intra-assay variation was acceptable, and thus all samples were 
included in the analysis.  
Table 3. Biomarker levels and comparison between different groups in the second part of the study
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Two subgroups were studied and compared: AF diagnosed patients vs patients not 
diagnosed with AF, and AF diagnosed by Holter devices (hAF) vs patients not diagnosed 
with AF.  
In the first comparison, NT-proBNP was significantly higher in individuals with 
AF compared to no AF [643.65 pg/ml (IQR 155.72–1339.25) vs. 64.28 pg/ml (IQR 
37.08–133.10), p < 0.0001], while the remaining biomarkers were not different between 
the two groups; also, the cut-off point of NT-proBNP of >95 pg/ml showed 95% 
sensitivity, 66.2% specificity, 41.3% positive predictive value (PPV) and 98.1% negative 
predictive value (NPV) for detecting any AF. It was also demonstrated that AF burden 
correlated with NT-ProBNP (r=0.597, p=0.024).   
The second subgroup analysed, hAF vs No AF, showed that NT-proBNP levels 
varied between patients without AF (no AF ) and those with AF diagnosed by Holter 
devices (hAF) [64.28 pg/ml (IQR 37.08–133.10) vs. 128.3 pg/ml (IQR 97.69–191.3), p = 
0.031]. The rest of the biomarkers did not show notable differences. The cut-off point of 
NT-proBNP of >95 pg/ml had 85.7 % sensitivity, 66.2% specificity, 18.2% PPV and 
98.1% NPV to detect hAF. 
Figure 1. ROC Curve showing NT-proBNP discrimination power in the second part of the study
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 In the presence of AF, in addition to NT-proBNP, in the univariate analysis (Table 
2.), ischaemic heart disease, heart failure, the presence of valvulopathy, anticoagulant 
treatment and CHA2DS2-VASc were found to be as significant variables. The results of 
the logistic regression (Table 4) were obtained from all the variables associated with AF 
and/or AF diagnosed by Holter registry in the univariate analysis (Table 2), thereby 
reducing the significant variables to anticoagulants (OR = 18.90; 95% CI, 2.10–169.83; 
p = 0.09) and NT-proBNP >95 pg/ml (OR = 22.42; 95% CI, 2.74–183.15; p=0.04) as the 
only independent predictors of AF in the logistic regression analysis performed in the 
whole cohort. CHA2DS2-VASc was an independent AF predictor when considered alone 
in the regression analysis (OR = 2.29; 95% CI 1.16–4.44; p = 0.017), but P-value 
comparison hAF vs no AF was not significant. A source for confusion is likely related to 
how the CHA2DS2VASc score is included in guideline recommendations: if the sum of 
points exceeds a certain threshold, a recommendation of treatment is triggered. This 
approach is great when making dichotomous decisions. There is previous evidence about 
the use of CHA2DS2VASc score in patients without atrial fibrillation. The Cox model 
was applied just on the variables included in CHADsVASc score as covariates in the 
regression analysis. Certainly, this could improve the creation of a model including 
CHA2DS2VASc only and allow comparing its performance to another model including 
CHA2DS2VASc and variables that are not included in CHA2DS2VASc score; 
calculating integrated discrimination improvement (IDI) and net reclassification index 
(NRI) could facilitate decisions of clinical usefulness in future studies. 
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Table 4. Comparison according to atrial fibrillation diagnosis. 
 
 Univariate analysis 
P-value 
Regression  analysis 
P-value 
Coronary heart disease 0.008 0.247 
Heart failure 0.007 0.870 
Valvular disease 0.024 0.357 
Anticoagulation 0.000 0.09 
NT-proBNP >95 <0.0001 0.04 
CHA2DS2-VASc 0.035 0.017* 
* when considered alone in the regression analysis 
 
As for the variable NT-proBNP> 95 pg/ml as a cut-off applicable to systematic 
AF screening, it is lower as a cut-off point here than in other studies [55,56] that place it 
at ≥125 ng/L as a negative predictive value to be screened among individuals with newly 
detected AF and CHA2DS2-VASc parameters do not differ significantly with those 
without AF, so the populations are not identical. However, the conclusions were similar: 
NT-proBNP increased in individuals with newly detected AF and future studies could 
clarify if NT-proBNP can be used to correctly select individuals that benefit most from 
AF screening. 
The variable "Anticoagulation" should be interpreted as a discriminatory marker 
as soon as patients with diagnosed AF are anticoagulated. The global results reflect a 
significantly higher use of anticoagulants among those cases with AF in which 
opportunistic screening was performed. 
Finally, the result for CHA2DS2-VASc as an independent AF predictor when 
considered alone in the regression analysis agrees with previous publications [57-60] that 
showed its possible predictive value in the stratification of the risk of suffering from AF 
and / or stroke and not only as an indicator of anticoagulant treatment. 
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8. Discussion 
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8. Discussion 
Both parts of the study had the common goal of helping to establish a guided route 
for AF. As main results from this project, we established that a health program of case 
finding is a tool that increases the prevalence and incidence of AF, we revealed barriers 
for the case finding, and we identified that NT-proBNP is a marker that could be used in 
AF case finding.  
In the first phase, 61% of over 48,000 patients aged 60 and older underwent case 
finding for AF, thereby tripling the incidence of new AF cases detected compared to the 
control group. Case finding or/and screening are extremely useful secondary prevention 
measures; its basic purpose is to decrease the incidence of complications derived from 
important pathologies that can lead to significant disability, decrease mortality, and/or 
increase the quality of life of people affected by certain pathologies [61,62]. The 
effectiveness of case finding, in this case, was conditioned by variables including age, 
residence, institutionalization and comorbidities. Before this study, previous papers 
mainly focused on treatment barriers [63, 64], but no study has focused before on “not so 
clinical” barriers such as the frequentation of health services, age, place of residence and 
other comorbidities. Considering these variables and the implementation of new digital 
technologies could improve the results of AF case finding, especially for populations at 
higher risk of AF. Remarkably, 87% of the new AF cases had CHA2DS2VASc scores of 
≥ 2. 
 The variables associated with the lack of AF case finding should be considered in 
the implementation of a healthcare program. The first variable was the place of residence; 
patients in urban zones were less likely to have case finding for AF performed. This could 
be attributed to many causes, but in our territory, it could be because there are no urban 
municipalities in the two districts with a higher demographic age. Another variable to 
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consider is the association of the number of visits to the patient’s GP with the performance 
of opportunistic case finding. The study showed that if the number of visits increased, so 
did the possibility for performing case finding and thus detecting new AF cases. For this 
reason, the population could be encouraged to perform self-case finding [65] or we wait 
for that to happen [66] through pulse palpation and the use of new AF detection devices. 
Institutionalized patients were found to have less AF identified; we could explain this by 
the fact that these patients have fewer possibilities to access their GPs and have more 
comorbidities.  
 The results of the second phase of the study show that NT-proBNP could be used 
as a screening biomarker to detect even paroxysmal AF in asymptomatic, high-risk 
individuals. One of the main goals of this part of the study was to predict or diagnose 
paroxysmal AF through biomarkers and to use them as a first step in a screening workflow 
in an AF pathway. Our study differed from others [67,68] by not only classifying 
paroxysmal AF with a normal ECG, but by overcoming this limitation by recording the 
patients’ cardiac records using a Holter monitor, thereby detecting more cases of 
paroxysmal AF. This is the longest period over which asymptomatic individuals have 
been monitored to detect AF in a biomarker study, if we exclude studies using 
pacemakers. The inclusion in the study was performed before any biomarker 
determination and 4-week Holter monitoring was used as the gold standard to assess the 
usefulness of blood-based biomarkers in AF screening. A limitation of this part of the 
study might be the small number of participants, but after validating these results with a 
larger cohort, NT-proBNP could be implemented as part of a case finding program for 
AF in a defined AF pathway.  
 A specific cut-off point for AF case finding was proposed for the first time. NT-
proBNP with values > 95 pg/ml reached a high sensitivity in identifying AF (95%), even 
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in patients with paroxysmal AF (85.7%). Although NT-proBNP can be categorised as an 
unspecific biomarker for AF (it can be elevated in different chronic and acute diseases), 
high sensitivity is more useful than specificity for screening purposes. Although it might 
be suspected that elevated NT-proBNP levels were due to a higher burden of heart failure 
and other cardiovascular diseases in the AF subjects of our cohort, in the hAF group, there 
were few individuals with known comorbidities that could affect NT-proBNP levels. In 
fact, in this group, there were no cases of heart failure, and there were only differences in 
coronary heart disease when compared to individuals with no AF. In addition, the study 
was carried out at the outpatient clinic and, therefore, no patient was in a situation of acute 
decompensated heart failure. B‐type natriuretic peptide (BNP) and the stable N‐terminal 
portion of the prohormone NT‐proBNP are peptides synthesized by myocytes, 
predominantly in the left ventricle, in response to elevated wall stress. High natriuretic 
peptide levels correlate positively with cardiac filling pressures, making them excellent 
markers for abnormal LV wall stress; patients’ elevated NT‐proBNP levels independently 
predict an increased risk of developing AF [69]. The other biomarkers studied in this 
phase were not useful for AF case finding. It is also remarkable that a higher level of NT-
proBNP was associated with a higher AF burden (observed from continuous Holter 
monitoring). 
On the one hand, the limitations of this study include its non-randomisation and 
its duration compared with the follow-up visits with the patients. It is limited by its 
duration to minimal follow-up regarding stroke incidence in the patients. On the other 
hand, the small sample size and the small number of patients with diagnosed AF suggest 
that these results should be interpreted as hypothesis-generating. Eventually, the burden 
of AF will be important to consider and reuse. It can be defined as the duration of AF 
episodes during a certain time (varies in different studies) [70, 71]. The duration of AF 
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episodes and number of times shown in the record have yet to be deeply investigated, but 
they are useful in assessing the risk of developing clinically significant AF and thus the 
need for anticoagulant treatment. Currently, the burden of AF necessary to indicate 
anticoagulation is a matter of debate. 
It should be noted that this part presents the results of the pilot study of the 
AFRICAT project, which included only the first 100 patients as a prior evaluation of the 
methodological strategy and the detection of potential problems in the final inclusion 
phase, so it was not designed for multivariate analysis. However, it does highlight that, 
with due caution in interpreting the results, a cut-off point can be defined in a biomarker 
within the scope of routine care among primary care professionals; this biomarker can be 
used to increase the effectiveness of screening by identifying individuals at high risk of 
not only of AF, but also of strokes. The results of the AFRICAT study will confirm or 
modify this cut-off point, its ability to discriminate and the post-test probability in AF 
screening. 
The main global objective of the two parts of the study was to define and create a 
precise route for the screening, diagnosis and treatment of AF and thus to avoid the 
obvious adverse effects derived from said pathology. 
Our proposal is to aim case finding for AF to a general population sixty years or 
older excluding only those patients previously diagnosed with AF (Figure 6 Appendix). 
The general practitioner should first account for the social, demographic and other 
barriers identified in the first paper to try to find as many cases as possible. Once 
identified, as doctors, we should consider whether the patient could be defined as having 
a high risk of suffering from AF, using different scores, such as CHA2DS2VASC or the 
CHARGE-AF score, and with the aid of different devices such as Watch BP, Fibricheck, 
intelligent watches and wristbands, among others. If the patient is defined as having a 
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high risk of developing AF, we should investigate further and search for biological and 
or echocardiographic criteria for AF. In the case of this study, NT-proBNP >95 pg/ml 
proved to be elevated in patients with AF compared to the control patients. If any of the 
biological and/or echocardiographic criteria for AF are fulfilled, to confirm whether our 
patients suffer from AF, we should plan to use Holter monitoring. These two works 
should be considered together with the emerging evidence from other similar studies to 
have an accurate AF pathway for the detection of AF.  
The results of both articles define a more effective methodology in the active 
screening for AF. AF is an independent predictor of heart failure and stroke. The number 
of AF-related incident ischaemic strokes at age ≥80 years has trebled over the last 25 
years, despite the introduction of anticoagulants, and are projected to treble again by 
2050, along with the number of systemic emboli. Improved prevention in older people 
with AF should be a major public health priority. Overall, this highlights the high costs 
associated with different cardiovascular factors in an ageing society and also the cost of 
previously unknown AF-associated strokes. These progressive increases in overall burden 
justify the investigation of methodologies and their cost-effectiveness ratios to better 
direct prevention and treatment strategies. 
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9. Conclusions 
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9. Conclusions 
1) The performance of opportunistic case finding is associated with a significant increase 
in the recorded prevalence and incidence of AF. If proper and aimed case finding is 
eventually done in a high-risk population (defined and categorized by risk scales), the 
detection of new cases of AF will be significantly higher. 
 
2) There is a relationship between the performance of opportunistic case finding and 
factors like the frequent use of health services, age, place of residence and comorbidities. 
These should be considered in an AF case finding pathway in primary care. 
 
3) NT-proBNP may be useful as a screening biomarker for AF in asymptomatic high-risk 
populations with a promising cut-off point of 95 pg/ml, but this requires further 
validation.  
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10. Future Research proposals  
For future objectives, we should first try to better identify and categorize patients 
at high risk of AF with more accurate scales and try to break as many barriers to access 
as possible.  
 Our second and short-term objective is for NT-proBNP >95 pg/ml to have external 
validation with a larger cohort of patients to prove if it is still valid and establish a more 
accurate cut-off point. Also, more biomarkers should be identified and tested to find the 
most useful for the early diagnosis of AF.   
 The third objective is to establish the needed time for a Holter device to diagnose 
a patient with AF. Also, we should find more comfortable devices with higher battery 
capacity.  
 Future studies should further analyse and test different watches and or wristbands, 
which could allow us to screen a large population without creating additional cost or time 
burdens for GPs.  
 The last objective is to evaluate and test whether anticoagulation should be 
initiated before AF identification in certain patients with a very high risk of AF after an 
evaluation based on clinical, ECG, imaging and biological markers. The burden of AF 
should also be evaluated before deciding to anticoagulate. 
Future research should focus on cost-utility analysis using a patient-level Markov 
decision analytic model with a lifetime horizon to determine lifetime costs, quality-
adjusted life years and the incremental cost-effectiveness ratio of active screening for AF 
with new technologies and biomarkers, particularly in relation to routine care in patients 
at high risk of atrial fibrillation.   
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12.1. Figures  
 
12.1.1. Figure 1. WHO attributes of a good screening program. 
1. Important health program 
2. Available treatment 
3. Facilities for diagnosis and treatment 
4. Asymptomatic phase of disease 
5. The test should be acceptable to the population 
6. There should be a test for the condition 
7. Natural history understood; agreement on policy 
8. There should be an agreed policy on whom to treat 
9. Cost of case finding balanced with overall costs 
10. Tests should be sensitive  
11. Screening should be a continuous process 
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12.1.2. Figure 2. Screening tools. EHRA consensus document.
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12.1.3. Figure 3. New screening devices.
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Zungsontiporn Nath, Link Mark S. Newer technologies for detection of atrial 
fibrillation BMJ 2018; 363 :k3946 
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12.1.4. Figure 4. Current guidelines in Primary Care. 
 
 
Freedman at al. Circulation. 2017;135:1851–1867. DOI: 10.1161/CIRCULATIONAHA.116.026693 
 
Visit www.afscreen.org for more information. 
 
 
 
UNIVERSITAT ROVIRA I VIRGILI 
NEW PATHWAYS FOR EARLY IDENTIFICATION OF ATRIAL FIBRILLATION IN THE COMMUNITY 
Juan Ballesta Ors  
 
78 
 
12.1.5. Figure 5. Systematic vs opportunistic screening for AF. 
 
 
 
Petryszyn P, Niewinski P, Staniak A, et al. Effectiveness of screening for atrial fibrillation and its 
determinants. A meta-analysis. PLoS One. 2019;14(3):e0213198. Published 2019 Mar 20. 
doi:10.1371/journal.pone.0213198 
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12.1.6. Figure 6. Atrial fibrillation Pathway (AFOSS Study, 2020). 
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12.2. Table 
12.2.1. Table 1. Summary of Studies Regarding Screening for Atrial Fibrillation (≥2015).  
 
 
Name of Study 
Main objective 
Target 
Population 
Conclusions 
Year 
Number of participants 
Clinical Trial 
LOOP-Study  Screening for AF episodes lasting ≥6 
minutes (AF) with implantable loop 
recorder for 40 months of continuous 
monitoring randomized 3:1 to control 
(n=4500) 
≥70 years old and 
have ≥1 stroke risk 
factors 
AF was detected in 209 (35%) of the patients 2015 
N 6000 
NCT02036450 
PIAAF-FP  
Pulse palpation vs BPM vs ECG. 
Screening 
<90 years No Results Posted 
2015 
N 2174 
NCT02262351 
PIAAF-HOME  
AF screening in primary care patients 
using the ZIO XT Patch, a wearable 
adhesive patch monitor that provides 
continuous ECG recording for up to 14 
days, 
>75 years ECG patch monitor is superior to standard care for AF detection 
2015 
N 856 
NCT02392754 
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Incident AF – PREVEND  
9.7 ± 2.3 years of follow-up for all 
inhabitants of the city of Groningen, the 
Netherlands 
Baseline screening program 
28 to 75 years old The overall incidence rate of AF was 3.3 per 1,000 person-years 2015 
N 8265 
D2AF  
Pulse palpation vs BPM vs ECG. 
Screening 
>65 years No Results Posted 
2015 
N 19200 
NTR 4914 
ASSERT III  Determine the incidence of sub-clinical 
(silent) atrial fibrillation (AF) among 
elderly patients with hypertension and at 
least one other risk factor for AF. 
Wireless external loop monitor for 30 to 
60 days 
80 Years and older 
Monitoring will detect AF in at least 10% of patients who would be 
potential candidates for anticoagulant therapy 
2015 
N 129 
NCT02401854 
  
STROKESTOP Study 
Define the prevalence of untreated atrial 
fibrillation (AF) in a systematic screening 
intermittent ECG recordings 
75-76 years 
A previous diagnosis of AF was known in 9.3%. Total AF 
prevalence in the screened population was 12.3% 
2015 
N 7173 
NCT01593553 
    
  
  
Taggar et al. Systematic review and meta-analysis Blood pressure monitors and 12-lead ECG have the most accuracy 
2015     
N 15129     
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mSToPS 
Identify a high-risk cohort suitable for 
screening for asymptomatic atrial 
fibrillation at the end of the 4-month 
monitoring period in a mobile health 
technology-enabled home monitoring 
program. 
55 Years and older No Results Posted 
2015 
N 2274 
Area rural (Ireland)  Opportunistic screening. Over 6 months, 
subjects were screened by local General 
Practitioners using radial pulse palpation 
confirmed by 12 lead Electrocardiogram. 
65 years and older 735 (10.1%) had known AF and 55 (0.76%) had newly detected AF 
2016 
N 7262 
DOFA_AP  
Opportunistic vs symptomatic patients >65 years No differences 2017 
N 5465 
AFFORD  
Opportunistic; Denmark >65 years Detection of new AF-patients 2017 
N 970 
Akershus Cardiac Examination 
1950 study   2017 
Screening for atrial fibrillation >65 years 
Identified undiagnosed AF in 0.9%. The total prevalence of AF was 
7.6% 
N 1510 2-week intermittent ECG screening 
CHA2DS2-VASc 
score ≥2 for men 
or ≥ 3 for women 
Petryszyn 
Meta-analysis about the effectiveness of 
screening for AF 
  
Active screening for AF is effective beginning from 40 years of age. 
Systematic screening seems more effective than opportunistic 2019 
N 88786 
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Screening for Actionable Atrial 
Fibrillation During Preoperative 
Consultation With the 
MyDiagnostick 
Presence of AF pre-operatory 65 Years and older 
Analysed the rhythm for the presence of AF and distinguished AF 
from normal cardiac rhythms by measuring RR-irregularity 
2016 
N 505 
NCT02960334 
Opportunistic Screening in 
Pharmacies for Atrial Fibrillation 
in Seniors (AF-Stroke) 
Whether an opportunistic AF screening 
with a hand-held diagnostic tool in a 
German pharmacy setting is useful for 
detecting unknown AF among people 
aged 65 and older 
(>65 Years) No Results Posted 
2016 
N 7606 
NCT03004859 
Systematic Screening for Atrial 
Fibrillation-potential Patients to 
Increase AF Detection Rate 
(SCAN-AF) Number of subjects screened with AF 
identified at Index Visit (4 weeks) 
Individuals 65 years 
of age or older with 
moderate-to-high 
risk of stroke 
No Results Posted 
2017 
N 1316  
NCT03313167 
Atrial Fibrillation Screening in 
Nursing Homes 
Number of participants with atrial 
fibrillation on any of four rhythm 
recordings 
Age ≥75 years No Results Posted 
2019 
N 245 
NCT03860246 
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Home-Based Screening for Early 
Detection of Atrial Fibrillation in 
Primary Care Patients Aged 75 
Years and Older (SCREEN-AF) 
Detection of new atrial fibrillation or 
flutter 
Age ≥75 years No Results Posted 
2015 
N 856 
NCT02392754 
Screening for Atrial 
Fibrillation (AF)-Potential Patients 
to Increase AF Detection Rate 
Number of subjects screened with AF 
identified at Index Visit 
[Time Frame: Up to 4 weeks] 
65 Years and older No Results Posted 2017 
N 1316 
NCT03313167 
Novel Methods for Arrhythmia 
Detection: Preliminary Study 
Chest strap and PPG-device data quality All No Results Posted 
2018 
N 220 
NCT03721601 
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A Digital Non-interventional Atrial 
Fibrillation (AF) Screening Study 
With Commercial Pulse Detection 
Systems  
The rate of correctly detected sinus 
rhythm signals by CPDS in reference to 
ECG (sensitivity of CPDS). 
Not posted No Results Posted 
2017   
N 165   
NCT02875106 
  
Opportunistic Screening in 
Pharmacies for Atrial 
Fibrillation in Seniors (>65 Years)  
·        Number of newly detected atrial 
fibrillation in adults from the age of 65 
by means of an opportunistic screening 
with an ECG hand-held diagnostic tool in 
a pharmacy setting 
 
65 Years and older No Results Posted 
2017 
·        The subject's behaviour change 
regarding diagnosis and therapy from the 
ECG measurement at a pharmacy at 8 
weeks and 12 months. 
 
N 7606 
·        Identification and description of 
new therapeutic measures. 
NCT03004859   
  ·        Performance of screening tests 
65 Years and older No Results Posted 
Program for the Identification of 
"Actionable" Atrial Fibrillation in 
the Family Practice Setting  
·        Cost of each method per case of 
actionable AF detected 
2015 
·        Cost-effectiveness measures based 
on each screening test and their potential 
impact on stroke and other clinical 
endpoints 
N 2174   
NCT02262351   
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·        Incidence of newly diagnosed atrial 
fibrillation 
50 Years to 100 
Years  
No Results Posted 
Screening for Atrial Fibrillation in 
Native AmeRicans Using iPhone 
ECG  
·        Prevalence of guideline-directed 
anticoagulant use among participants 
who were found to have atrial fibrillation 
2018   
N 1500   
NCT03740477   
Screening for Atrial 
Fibrillation Among Older Patients 
in Primary Care Clinics  
·        Incident AF during the study period 
65 Years and older No Results Posted 
2018 
·        Incident AF associated with a 
primary care encounter during the study 
period 
 
N 35308 
·        New oral anticoagulation 
prescription during the study period 
NCT03515057   
Risk-Based Screening for the 
Evaluation of Atrial 
Fibrillation Trial 
·        New detected (and centrally 
confirmed) cases of atrial 
fibrillation/flutter > 2 minutes 
 
55 Years and older No Results Posted 
2018 ·        Initiation of oral anticoagulation 
N 755   
NCT03911986   
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Systematic Screening With 
Electrocardiogram for 
Unknown Atrial Fibrillation in 65 
Years Old and Above People in 
Nursing Home  
·        Presence of atrial fibrillation on 
electrocardiogram 
65 Years and older No Results Posted 
2015 ·        Presence of irregular pulse 
N 287   
NCT02892578 
  
Silent Atrial 
Fibrillation - Screening of High-
risk Groups for Atrial 
Fibrillation (The Silence Study)  
·        Number of participants with silent 
atrial fibrillation as assessed by handheld 
ECG measurements in high-risk heart 
failure patients 
 
65 Years and older No Results Posted 
2016 
·        Number of participants with silent 
atrial fibrillation as assessed by handheld 
ECG measurements in high-risk type 2 
diabetes patients 
 
N 1622 
·        Number of participants with 
supraventricular ectopic activity 
NCT02893215   
  
·        Utilization rates of evidence-based 
stroke prevention therapy 
65 Years and older No Results Posted 
Hong Kong Outpatient 
AF Screening Using Single-lead 
ECG Device  
·        Rates of newly diagnosed atrial 
fibrillation in elderly >65 years of age 
 
2015 
·        Clinical outcomes including death, 
stroke and bleeding 
N 500   
NCT02409654   
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mHealth Screening to Prevent 
Strokes  
·        Incidence of newly diagnosed AF 
55 Years and older No Results Posted 
2015 
·        Prevalence of atrial fibrillation 
 
N 2274 
·        Time to first event of the combined 
endpoint of stroke, systemic emboli or 
MI in patients diagnosed with AF in 
monitored vs. control cohorts. 
NCT02506244 
·        Difference in total healthcare costs 
in AF cohorts of monitored and controls 
Screening for Sleep Apnea in 
Patients Undergoing Atrial 
Fibrillation Ablation  
·        Prevalence of sleep apnea in 
patients with atrial fibrillation 
18 Years and older No Results Posted 2015 
·        Arrhythmia recurrence 
 
N 100 
·        Need for antiarrhythmic 
medications 
NCT02332096 ·        CPAP compliance when prescribed 
 
Diagnosis of atrial fibrillation during 
continuous monitoring in a Stroke unit 
within six months of stroke 
18 Years and older No Results Posted 
Stepwise Screening for 
Silent Atrial Fibrillation After 
Stroke  
2018 
N 300 
NCT03570060 
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RedStroke - Reducing Europe's 
Stroke Incidence  
·        Prevalence of Atrial Fibrillation 
All ages No Results Posted 
2019 
·        Costs related to the AF screening 
 
N 2100 
·        Compliance of patients using the 
app 
NCT04108884   
  
Decreasing the incidence of Post-
Operative Atrial Fibrillation for Cardiac 
Surgery Patients 
18 Years and older No Results Posted 
Prevention of Postop Atrial 
Fibrillation Through Intraoperative 
Inducibility of Atrial 
Fibrillation and Amiodarone 
Treatment  
2017 
N 600 
NCT03868150 
A Study to Determine if 
Identification of 
Undiagnosed Atrial Fibrillation in 
People at Least 70 Years of Age 
Reduces the Risk of Stroke  
·        Occurrence of all strokes leading to 
hospitalization 
  
No Results Posted 
2019 
·        Occurrence of bleeding leading to 
hospitalization 
70 Years and older  
N 52000     
NCT04126486     
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·        Time to recurrence of AF after AF 
ablation 
 
18 Years to 79 
Years 
No Results Posted 
Sleep Apnea and Atrial 
Fibrillation Recurrence  
·        Cost-utility analysis of SAS 
screening by reporting health resource 
utilization 
 
2017 ·        Measure of health status EQ-5D 
N 280   
NCT02906839 
  
  
Atrial fibrillation (AF) diagnosis 
  
No Results Posted 
Atrial Fibrillation Research In 
CATalonia (AFRICAT)  
65 Years to 75 
Years  
2016   
N 500   
NCT03188484 
  
 
Newly detected in-hospital AF All ages No Results Posted 
Handheld ECG Tracking of In-
hOspital Atrial Fibrillation  
2018 
N 804 
NCT03197090 
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  ·        Performance of screening tests   
No Results Posted 
Program for the Identification of 
"Actionable" Atrial Fibrillation in 
the Family Practice Setting  
·        Cost of each method per case of 
actionable AF detected 
65 Years and older   
2015 
·        Cost-effectiveness measures based 
on each screening test and their potential 
impact on stroke and other clinical 
endpoints 
  
N 2174     
NCT02262351 
    
  
·        Patient-Reported Outcome 
Measures 
18 Years and older  No Results Posted 
Implementing Digital Health in a 
Learning Health System  
·        Patient-Reported Experience 
Measures 
2018 ·        Health Economic Outcomes 
N 500   
NCT03713333 
  
AFOSS 
Atrial fibrillation 60 Years and older 
Case finding is associated with a significant increase in the 
prevalence and incidence of AF.  
2017 
There is a relationship between the performance of opportunistic 
case finding and factors like the frequent use of health services, age, 
place of residence and comorbidities 
N 46374 NT-proBNP may be useful as a screening biomarker in AF  
NCT03589170 
A screening strategy based on NT-proBNP, alone or in combination 
with other biomarkers, might be of interest for the early initiation of 
anticoagulants, which could reduce cardioembolic stroke 
consequences 
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